^
Association details:
| Biomarker: | PTEN R233X |
|---|---|
| Cancer: | Melanoma |
| Drug: | Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma
Excerpt:
Patient 70 was on therapy for 29 weeks and achieved a partial response before acquiring an NRASQ60H mutation and a PTEN R233* nonsense mutation.
DOI:
10.1158/2159-8290.CD-13-0617
